Abstract
The 5FU prodrug capecitabine undergoes a 3-step enzymatic conversion, including the conversion of 5′DFRC into 5′DFUR by cytidine deaminase (CDA). The presence of CDA activity in blood led us to analyze the possible ex vivo conversion of 5′DFCR into 5′DFUR in blood samples. We thus examined the impact of the addition of a CDA inhibitor (tetrahydrouridine (THU) 1 μM final) in blood. Blood samples from 3 healthy volunteers were taken on tubes containing or not THU. Blood was spiked with 5′DFCR (20 μM final) (T0) and was maintained at room temperature for 2 h. Plasma concentrations of 5′DFRC and 5′DFUR were analyzed with an optimized HPLC assay. In the absence of THU, 5′DFUR was detectable as early as T0. The percent of 5′DFUR produced relative to 5′DFCR increased over time, up to 7.7 % at 2 h. In contrast, the presence of THU totally prevents the formation of 5′DFUR. The impact of THU for preventing the conversion of 5′DFCR was confirmed by the analysis of blood samples from 2 capecitabine-treated patients. Addition of THU in the sampling-tube before the introduction of blood is thus strongly recommended in order to guarantee accurate conditions for reliable measurement of capecitabine metabolites in plasma, and thus faithful pharmacokinetic data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
